TD Private Client Wealth’s BeOne Medicines Ltd ONC Stock Holding History

TD Private Client Wealth’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	-$813	–	1338
2021 Q4	$813	Hold	3	–	–	﹤0.01%	1083
2021 Q3	$1.09K	Hold	3	–	–	﹤0.01%	1092
2021 Q2	$1.03K	Hold	3	–	–	﹤0.01%	1106
2021 Q1	$1.04K	Hold	3	–	–	﹤0.01%	1066
2020 Q4	$775	Hold	3	–	–	﹤0.01%	1041
2020 Q3	$859	Hold	3	–	–	﹤0.01%	979
2020 Q2	$565	Buy	+3	New	+$488	﹤0.01%	1012

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

TD Private Client Wealth's ONC Position: Q1 2022 in Review

TD Private Client Wealth sold out of BeOne Medicines Ltd (ONC) in Q1 2022, closing a stake of 3 shares — an estimated $813 sold.

TD Private Client Wealth first reported a position in ONC in Q2 2020 and held it in 7 quarters. The position peaked at $1.09K in Q3 2021. 239 funds tracked by Wall St. Rank hold ONC as of Q1 2022.

TD Private Client Wealth reported no remaining BeOne Medicines Ltd position as of Q1 2022 after selling out during the quarter.
TD Private Client Wealth sold 3 BeOne Medicines Ltd shares in Q1 2022, an estimated $813.
TD Private Client Wealth first reported a position in BeOne Medicines Ltd in Q2 2020 and held it in 7 quarters.
TD Private Client Wealth's BeOne Medicines Ltd position peaked at $1.09K in Q3 2021.
239 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2022.

Based on TD Private Client Wealth's 13F filing for Q1 2022, filed 16 Aug 2024.